TABLE 2.
Clinical characteristics of patients with percutaneous endoscopic gastrostomy site infection with and without head and neck cancer
| Variables | Nonhead and neck cancer | Head and neck cancer | Total | P | Adjusted ORs (95% CI) | P |
|---|---|---|---|---|---|---|
| n = 25 (%) | n = 42 (%) | n = 67 (%) | ||||
| Male | 17 (68.0) | 33 (78.6) | 50 (74.6) | .391 | ||
| Age (years), mean ± SD | 64.10 ± 14.00 | 58.74 ± 8.02 |
62.90 ± 11.86 |
.001 | 0.932 (0.859‐1.012) | .093 |
| Underlying disease | ||||||
| Neurologic diseases | 21 (84.0) | 1 (2.4) | 22 (32.8) | <0.001 | 0.023 (0.002‐0.324) | .005 |
| Solid cancer | 2 (8.0) | 42 (100) | 44 (65.6) | <0.001 | ||
| Diabetes mellitus | 6 (24.0) | 4 (9.5) | 10 (14.9) | .157 | ||
| Heart diseases | 4 (16.0) | 2 (4.8) | 6 (9.0) | .186 | ||
| Chronic lung diseases | 2 (8.0) | 0 (0.0) | 2 (3.0) | .136 | ||
| Chronic renal diseases | 2 (8.0) | 3 (2.3%) | 13 (4.1) | .184 | ||
| Chronic liver diseases | 0 (0.0) | 1 (2.4) | 1 (1.5) | 1.000 | ||
| Charlson Comorbidity Index score | 3.04 ± 1.24 | 1.48 ± 0.74 | 2.06 ± 1.22 | <0.001 | 0.451 (0.191‐1.068) | .070 |
| Late infection | 17 (68.0) | 31 (73.8) | 48 (71.6) | .780 | ||
| Prophylactic antibiotics | 23 (92.0) | 41 (97.6) | 64 (95.5) | .230 | ||
| Prior antibiotic therapy | 14 (56.0) | 33 (78.6) | 47 (70.1) | .051 | 1.598 (0.288‐8.854) | .591 |
| Penicillin | 4 (16.0) | 15 (35.7) | 19 (24.8) | .083 | ||
| Cephalosporin | 3 (12.0) | 10 (23.8) | 13 (19.4) | .237 | ||
| Fluoroquinolone | 6 (24.0) | 5 (11.9) | 11 (16.4) | .196 | ||
| Carbapenems a | 3 (12.0) | 5 (11.9) | 8 (11.9) | .991 | ||
| Glycopeptide b | 5 (20.0 | 8 (19.0) | 13 (19.4) | .924 |
Note: Values are presented as no. (%) unless otherwise indicated.
Abbreviations: CI, confidence interval; OR, odds ratio; SD, standard deviation.
a
Includes imipenem, meropenem.
b
Includes vancomycin and teicoplanin.